It doesn't get much more dependable and lucrative than the healthcare industry.

When it comes to dividend stocks, no other sector has been more reliable than the healthcare sector. No matter the economic ...

AbbVie (ABBV) - a pharmaceutical company developing and selling specialized therapies - hit a 5-day winning streak, with ...

Humira plan is working brilliantly, but a subtle shift in the growth rate of one of its two key drugs deserves a much closer ...

ABBV is trading near the top of its 52-week range and above its 200-day simple moving average. Price change The price of ABBV shares has decreased $1.26 since the market last closed. This is a 0.50% ...

The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?

AbbVie knows how to plan ahead.

AbbVie’s $10.9B Apogee deal strengthens immunology beyond Humira, adds Zumilokibart optionality, and may be undervalued. See ...

Some valuation metrics suggest that AbbVie is a cheap stock. The company's growth prospects through 2030 look attractive. AbbVie is also an excellent dividend stock. 10 stocks we like better than ...

AbbVie shares snapped six straight sessions of gains on Tuesday, as the stock was 1.3% lower at $251.13. The biopharmaceutical company gained 10.6% in the preceding six sessions.

AbbVie stock (NYSE: ABBV) experienced a 5% decline yesterday, and the reason is evident: the U.S. FDA has just approved Johnson & Johnson’s Icotyde, the first oral IL-23 inhibitor on the market. This ...